-
公开(公告)号：US20110076300A1
公开(公告)日：2011-03-31
申请号：US12870718
申请日：2010-08-27
IPC分类号： A61K39/095 , C07K16/00 , C07H21/00 , A61K39/00 , A61P31/04 , A61P37/04 , C12N15/63 , C12N1/21 , C12N1/00
CPC分类号： C07K14/22 , A61K39/00 , C07K2319/00
摘要： fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.
摘要翻译： fHBP是脑膜炎奈瑟菌中的蛋白质。 已知三个fHBP家族。 为了增加fHBP蛋白引起家族之间交叉反应的抗体的能力，选择或改造fHBP以具有在给予宿主动物后可引发广谱杀菌抗脑膜炎球菌抗体的序列。
-
公开(公告)号：US20110020390A1
公开(公告)日：2011-01-27
申请号：US12918729
申请日：2009-02-20
IPC分类号： A61K39/385 , C07K2/00 , C12N15/31 , C12N15/63 , C12N1/00 , C12N1/21 , A61K39/095 , A61P37/04
CPC分类号： A61K39/095 , A61K39/00 , C07K14/22
摘要： fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.
摘要翻译： fHBP是脑膜炎奈瑟菌中的蛋白质。 已知三个fHBP家族。 为了增加fHBP蛋白引起家族之间交叉反应的抗体的能力，选择或改造fHBP以具有在给予宿主动物后可引发广谱杀菌抗脑膜炎球菌抗体的序列。
-
公开(公告)号：US09636393B2
公开(公告)日：2017-05-02
申请号：US10148533
申请日：2000-11-29
IPC分类号： A61K39/095 , A61K39/00 , A61K39/42 , A61K47/48 , A61K39/116
CPC分类号： A61K39/095 , A61K39/116 , A61K47/6415 , A61K47/646 , A61K2039/55505 , A61K2039/55566 , A61K2039/6037 , A61K2039/6068
摘要： International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).
-
公开(公告)号：US07632513B2
公开(公告)日：2009-12-15
申请号：US10611398
申请日：2003-06-30
IPC分类号： A61K39/02
CPC分类号： C07K14/28 , A61K38/00 , A61K39/00 , C07K14/245 , C07K2319/00 , C12N2799/026 , Y02A50/472
摘要： An immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment thereof or the amino acid sequence of subunit A of an Escherichia coli heat labile toxin (LT-A) or a fragment thereof wherein the amino acids at, or in positions corresponding to Ser-63 and Arg-192 are replaced with another amino acid. The immunogenic detoxified protein is useful as vaccine for Vibrio cholerae or an enterotoxigenic strain of Escherichia coli and is produced by recombinant DNA means by site-directed mutagenesis.
-
55.发明授权Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines 失效霍乱毒素和毒素LT的免疫原性解毒突变体及其制备及其在制备疫苗中的应用
公开(公告)号：US6149919A
公开(公告)日：2000-11-21
申请号：US823120
申请日：1997-03-25
申请人： Mario Domenighini , Rino Rappuoli , Mariagrazia Pizza , Wim Hol
发明人： Mario Domenighini , Rino Rappuoli , Mariagrazia Pizza , Wim Hol
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61K39/106 , A61K39/108 , A61P31/04 , C07K14/195 , C07K14/245 , C07K14/28 , C07K14/41 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/31 , C12P21/02 , A61K39/02 , C12P21/06
CPC分类号： A61K38/164 , C07K14/245 , C07K14/28 , A61K39/00
摘要： An immunogenic detoxified protein comprising the amino acid sequence of subunit A of cholera toxin (CT-A) or subunit A of an Escherichia coli heat labile toxin (LT-A) or a fragment thereof wherein one or more amino acids at, or in positions corresponding to Val-53, Ser-63, Val-97, Tyr-104 or Pro-106 are replaced with another amino acid or deleted. Examples of specific replacements include Val-53-Asp, Val-53-Glu, Val-53-Tyr, Ser-63-Lys, Val-97-Lys, Val-97-Tyr, Tyr-104-Lys, Tyr-104-Asp, Tyr-104-Ser, Pro-106-Ser. The immunogenic detoxified protein is useful as vaccine for Vibrio cholerae or an enterotoxigenic strain of Escherichia coli and is produced by recombinant DNA means by site-directed mutagenesis.
摘要翻译： 包含霍乱毒素（CT-A）亚基A或大肠杆菌热不稳定毒素（LT-A）的亚单位A或其片段的氨基酸序列的免疫原性解毒蛋白，其中一个或多个氨基酸位于 对应于Val-53，Ser-63，Val-97，Tyr-104或Pro-106被替换为另一个氨基酸或缺失。 具体替代的实例包括Val-53-Asp，Val-53-Glu，Val-53-Tyr，Ser-63-Lys，Val-97-Lys，Val-97-Tyr，Tyr-104-Lys，Tyr-104 -Asp，Tyr-104-Ser，Pro-106-Ser。 免疫原性解毒蛋白质可用作霍乱弧菌或大肠杆菌肠毒素菌株的疫苗，并通过重组DNA方法通过定点诱变产生。
-
公开(公告)号：US07700119B2
公开(公告)日：2010-04-20
申请号：US11264676
申请日：2005-11-01
IPC分类号： A61K39/095 , C07H21/04 , C12P21/04 , C07K14/00
CPC分类号： C07K14/22 , A61K39/00 , Y02A50/466
摘要： An 85 kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.
摘要翻译： 来自脑膜炎奈瑟氏球菌和淋病奈瑟氏球菌的85kDa抗原已被克隆，测序和表达。 该抗原对于脑膜炎奈瑟氏球菌的不同菌株，血清型和血清型以及淋病奈瑟氏球菌，多糖和内酰胺酶是常见的。 脑膜炎奈瑟氏球菌（血清群A和B）和淋病奈瑟氏球菌的蛋白质序列高度同源。
-
57.发明授权Pertussis toxin mutants, Bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines 失效百日咳毒素突变体，能够产生这种突变体的博德氏菌菌株及其在开发抗百日咳疫苗中的应用公开(公告)号：US07666436B1
公开(公告)日：2010-02-23
申请号：US08431673
申请日：1995-05-02
IPC分类号： A61K39/10 , C07K14/235 , C07H21/04
CPC分类号： C07K14/235 , A61K39/00 , A61K39/099
摘要： New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the amino acid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly44, Thr53 and Gly80 of subunit S1 amino acid sequence is deleted and substituted by a different amino acid residue selected in the group of natural amino acids; Bordetella strains capable of providing and secreting said PT mutants and means and methods for obtaining them are also described. The Bordetella strains and the PT mutants produced by them are particularly suitable for the preparation of effective cellular and acellular antipertussis vaccines.
摘要翻译： 新百日咳毒素（PT）突变体被描述为具有免疫活性且具有降低或无毒性的特征，其特征在于至少一个氨基酸残基Glu129，Asp11，Trp26，Arg9，Phe50，Asp1，Arg13，Tyr130，Gly86，Ile88， 亚基S1氨基酸序列的Tyr89，Tyr8，Gly44，Thr53和Gly80缺失，并被天然氨基酸组中选择的不同氨基酸残基取代; 还描述了能够提供和分泌所述PT突变体的Bordetella菌株及其获得方法和方法。 由它们生产的博德氏菌属菌株和PT突变体特别适用于制备有效的细胞和无细胞的抗百日咳疫苗。
-
58.发明授权Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine 失效具有改变的毒性的免疫活性多肽可用于制备抗百日咳疫苗公开(公告)号：US07410646B1
公开(公告)日：2008-08-12
申请号：US08261692
申请日：1994-06-17
IPC分类号： A61K39/10 , C07K14/235
CPC分类号： C07K14/235 , A61K39/00
摘要： Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganism transformed with a hybrid plasmid including the gene/s which codes for at least one of said polypeptides in a suitable medium and recovering the desired polypeptide from the cells or from the culture medium.
摘要翻译： 无毒性或降低毒性的免疫活性多肽可用于制备抗百日咳疫苗。 用于制备所述多肽的方法，其包括用合适培养基培养用包含编码所述多肽的至少一种的基因的杂交质粒转化的微生物，并从所述细胞或培养基中回收所需的多肽。
-
公开(公告)号：US20060166344A1
公开(公告)日：2006-07-27
申请号：US10526113
申请日：2003-09-01
申请人： Mariagrazia Pizza , Davide Serruto , Rino Rappuoli
发明人： Mariagrazia Pizza , Davide Serruto , Rino Rappuoli
IPC分类号： C12N9/00
CPC分类号： A61K39/095 , A61K2039/55555 , C07K14/22 , C12N1/06 , C12N1/20 , C12N13/00
摘要： Existing methods of meningococcal OMV preparation involve the use of detergent during disruption of the bacterial membrane. According to the invention, membrane disruption is performed substantially in the absence of detergent. The resulting OMVs which retain important bacterial immunogenic components, particularly (i) the protective NspA surface protein, (ii) protein NMB2132 and (iii) protein NMB 1870. A Typical process involves the following steps: (a) treating bacterial cells in the substantial absence of detergent; (b) centrifuging the composition from step (a) to separate the outer membrane vesicles from treated cells and cell debris, and collecting the supernatant; (c) performing a high speed centrifugation of the supernatant from step (b) and collecting the outer membrane vesicles in a pellet; (d) re-dispersing the pellet from step (c) in a buffer; (e) performing a second high speed centrifugation in accordance with step (c), collecting the outer membrane vesicles in a pellet; (f) re-dispersing the pellet from step (e) in an aqueous medium.
摘要翻译： 脑膜炎球菌OMV制剂的现有方法涉及在细菌膜破坏期间使用洗涤剂。 根据本发明，膜破坏基本上在没有洗涤剂的情况下进行。 所产生的OMV保留了重要的细菌免疫原性成分，特别是（i）保护性NspA表面蛋白，（ii）蛋白NMB2132和（iii）蛋白NMB1870。典型的方法包括以下步骤：（a） 不含洗涤剂; （b）将来自步骤（a）的组合物离心以将外膜囊泡与经处理的细胞和细胞碎片分离，并收集上清液; （c）对来自步骤（b）的上清液进行高速离心并将颗粒中的外膜囊泡收集; （d）将来自步骤（c）的沉淀物重新分散在缓冲液中; （e）根据步骤（c）进行第二高速离心，将外膜囊泡收集在颗粒中; （f）将来自步骤（e）的沉淀物重新分散在水性介质中。
-
公开(公告)号：US20050244436A1
公开(公告)日：2005-11-03
申请号：US10984376
申请日：2004-11-09
IPC分类号： C12N15/09 , A61K38/16 , A61K39/00 , A61K39/095 , A61P31/04 , C07K14/22 , C12N15/31 , C12N1/20
摘要： Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N.meningitidis and N.gonorrhoeae.
摘要翻译： 组合物包含来自奈瑟氏球菌细菌的第一生物分子和来自奈顿球菌细菌的第二生物分子。 术语“生物分子”包括蛋白质和核酸。 优选的奈瑟氏菌属是脑膜炎奈瑟氏球菌和淋病奈瑟氏球菌。
-
-
-
-
-
-
-
-
-
搜索结果
118 条记录 (耗时 0.05 秒)
